By Suherman Candra Maholtra 
New clinical research presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) has revealed that adults living with established heart disease who receive a shingles vaccine experience nearly half the rate of major adverse cardiovascular events compared to those who remain unvaccinated. The study, which analyzed data from hundreds of thousands of patients across the United States, suggests that the shingles vaccine provides a potent "cardioprotective" effect, potentially reducing the incidence of heart attacks, strokes, and all-cause mortality by a margin comparable to major lifestyle interventions such as smoking cessation.
The research arrives at a critical time for public health as medical professionals seek to understand the systemic links between viral infections, inflammation, and chronic cardiovascular conditions. Led by Robert Nguyen, MD, a resident physician at the University of California, Riverside, the study underscores a growing body of evidence suggesting that immunizations against common viral pathogens may serve as an essential tool in the secondary prevention of cardiovascular disease.
The Intersection of Viral Infection and Cardiovascular Risk
Atherosclerotic cardiovascular disease (ASCVD), characterized by the accumulation of plaque within the arterial walls, remains the leading cause of death globally. While traditional risk factors such as hypertension, hyperlipidemia, and diabetes are well-documented, the role of acute and chronic inflammation triggered by viral infections has become a focal point of modern cardiology.
Shingles, or herpes zoster, is caused by the reactivation of the varicella-zoster virus (VZV), the same pathogen responsible for chickenpox. After an initial infection, the virus remains dormant in the nervous system. As the immune system weakens with age or stress, the virus can reactivate, causing a painful, blistering rash and, in some cases, debilitating postherpetic neuralgia.
However, the impact of shingles extends beyond the skin and nerves. Previous epidemiological studies have demonstrated that a shingles outbreak can trigger a systemic inflammatory response, leading to an increased risk of blood clots, vasculitis, and the rupture of atherosclerotic plaques. These physiological stressors significantly elevate the risk of myocardial infarction (heart attack) and cerebrovascular accidents (stroke) in the weeks and months following a shingles episode.
Methodology and Scope of the TriNetX Analysis
To quantify the protective benefits of the shingles vaccine, Dr. Nguyen and his team utilized TriNetX, a massive global health research network that provides access to de-identified electronic health records from millions of patients. The study focused specifically on a high-risk cohort: adults aged 50 and older who had already been diagnosed with atherosclerotic heart disease.
The researchers identified 246,822 individuals meeting the criteria between 2018 and 2025. To ensure a rigorous comparison, the study utilized a propensity score matching technique. This allowed researchers to create two balanced groups: 123,411 individuals who had received at least one dose of a shingles vaccine (either the recombinant Shingrix or the older live-attenuated Zostavax) and an equal number of unvaccinated controls.
The groups were matched not only for age and sex but also for a wide array of comorbidities and socioeconomic factors. This included adjustments for housing stability, economic circumstances, employment status, and educational background—factors collectively known as the social determinants of health, which can often skew medical data if left unaddressed.
Significant Reductions in Major Adverse Cardiac Events (MACE)
The findings of the study were stark, showing a consistent and substantial reduction in nearly every measured cardiovascular outcome among the vaccinated group. Researchers focused on the one-year window following vaccination to capture the immediate and intermediate protective effects.
According to the data:
- Major Adverse Cardiac Events (MACE): Vaccinated individuals were 46% less likely to experience a composite endpoint of serious heart-related events.
- All-Cause Mortality: The risk of death from any cause was reduced by a staggering 66% in the vaccinated cohort.
- Myocardial Infarction: The incidence of heart attacks dropped by 32%.
- Stroke: The risk of cerebrovascular events was 25% lower among those who received the vaccine.
- Heart Failure: Vaccinated patients saw a 25% reduction in the risk of developing or exacerbating heart failure.
"These findings are quite remarkable," Dr. Nguyen stated in his analysis. "The magnitude of the risk reduction we observed—particularly the 46% reduction in MACE—suggests that the vaccine’s benefits are not just statistically significant, but clinically transformative for patients already struggling with heart disease."
Comparing Vaccine Benefits to Traditional Interventions
One of the most striking aspects of the study was the comparison of the vaccine’s efficacy to other well-established medical interventions. Dr. Nguyen noted that the reduction in cardiovascular risk associated with the shingles vaccine is comparable to the benefits seen when a long-term smoker successfully quits the habit.
In the field of cardiology, few interventions offer a nearly 50% reduction in major events within a single year. While statins and antiplatelet therapies are the cornerstones of ASCVD management, the addition of a shingles vaccine appears to offer an independent layer of protection. This has led researchers to speculate that the vaccine may work by preventing the acute inflammatory "surge" that accompanies viral reactivation, thereby maintaining the stability of existing arterial plaques.
Contextualizing the Findings within the ACC.26 Framework
The presentation of this data at the American College of Cardiology’s Annual Scientific Session (ACC.26) places the study at the center of the global conversation on "immunocardiology." The ACC session is one of the most prestigious gatherings of cardiovascular professionals in the world, where new guidelines are often debated and established.
The study builds upon earlier research, including a notable 2025 study which found that shingles vaccination was linked to a 23% reduction in cardiovascular events among generally healthy adults. Dr. Nguyen’s research specifically targets the "highest risk" population—those who already have damaged arteries—suggesting that the more vulnerable a patient’s heart is, the more they stand to gain from the immunization.
Furthermore, the study contributes to the growing "beyond the rash" narrative for the shingles vaccine. Recent separate studies have suggested a potential link between shingles vaccination and a reduced risk of dementia, leading scientists to believe that VZV may play a broader role in chronic age-related systemic decline than previously understood.
Addressing Limitations and the "Healthy User" Bias
Despite the compelling data, the research team acknowledged several limitations inherent in observational studies using electronic health records. A primary concern in vaccine research is the "healthy user bias"—the tendency for individuals who seek out preventive care, like vaccines, to also engage in other heart-healthy behaviors, such as regular exercise, a balanced diet, and medication adherence.
While the researchers adjusted for many socioeconomic and health-related variables, it is difficult to entirely isolate the vaccine’s effect from a patient’s overall lifestyle. Additionally, the study’s primary focus was on the first year following vaccination. While previous data has suggested that the cardiovascular benefits could last up to eight years, further longitudinal studies are required to determine the exact duration of the shingles vaccine’s heart protection.
Public Health Implications and the Fight Against Disinformation
The clinical implications of this study are immediate. The Centers for Disease Control and Prevention (CDC) currently recommends the Shingrix vaccine for adults aged 50 and older, yet uptake remains inconsistent. In an era of increasing vaccine hesitancy and medical disinformation, Dr. Nguyen believes these findings provide a powerful new argument for clinicians.
"Sometimes patients are unsure about whether they should get a vaccine or not," Nguyen said. "These results provide another reason for them to elect to get the vaccine. It’s not just about avoiding a painful rash; it’s about protecting your heart and potentially extending your life."
If these findings are integrated into standard clinical practice, cardiologists may soon begin checking shingles vaccination status with the same regularity that they check cholesterol levels or blood pressure.
Conclusion and Future Outlook
The presentation of "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease" at ACC.26 marks a significant milestone in the study of viral-cardiovascular interactions. As the medical community moves toward a more holistic view of heart health, the role of the immune system and preventive vaccinations is becoming impossible to ignore.
For millions of Americans living with heart disease, the shingles vaccine may represent one of the most accessible and effective tools for reducing the risk of a life-altering cardiac event. As Dr. Nguyen concludes his presentation on March 30 in Chicago, the focus will likely shift toward updating clinical guidelines to reflect this dual-purpose benefit of the shingles immunization. Future research will likely explore whether other vaccines, such as those for influenza or RSV, offer similar synergistic benefits for patients with chronic cardiovascular conditions, further solidifying the link between infectious disease prevention and heart health.
